https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20210616-1401159/1401159_6-catm.pdf
Sorrento Therapeutics Reports Received FDA Clearance To Proceed With Trial For Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors
Anti-TROP-2 ADC with a drug payload SN38 (a DNA polymerase inhibitor) (ESG-401) has received FDA authorization to begin clinical trials in the US.
ESG-401 addresses a highly unmet need for the treatment
